Ibogaine Success Rates & Clinical Outcomes

Brown & Alper (2018): 50% of 30 subjects reported no opioid use one month after treatment, with improvements sustained through 12 months.

Alper et al. (1999): resolution of opioid withdrawal signs within 24 hours in 25 of 33 treatments, sustained through at least 72 hours.

Davis et al. (2017): in a survey of 88 people who took ibogaine for opioid problems, 80% reported withdrawal symptoms eliminated or drastically reduced.

Stanford MISTIC trial (n=30 veterans) showed 88% average PTSD reduction at 1-month follow-up.

9 of 10 patients at Beond Health (6,000+ treatments) report the treatment worked. 100% treatment retention.

Unlike chronic MAT, ibogaine typically requires one medically supervised session.

A systematic review of 24 studies covering 705 ibogaine-treated patients concluded that ibogaine and noribogaine show potential to reduce withdrawal severity and craving, while emphasizing cardiac risk (QT prolongation) and the absence of randomized controlled trials. No validated long-term abstinence rate exists in the published literature.

The landmark Stanford MISTIC trial treated 30 Special Operations veterans with magnesium-ibogaine for PTSD and TBI. Results: 88% average PTSD symptom reduction, 87% depression reduction, 81% anxiety reduction at 1 month. WHODAS disability scores dropped from 30.2 to 5.1 (effectively no disability). Remission at 1 month: 86% (PTSD), 83% (depression), 83% (anxiety). No unexpected or serious adverse events were reported. Open-label, no control group.

A prospective observational study of 14 patients receiving legal ibogaine treatment in New Zealand found significant reductions in opioid dependence (ASI-Lite) and depression (BDI-II) sustained over 12 months of follow-up. One participant died during treatment, underscoring the need for medical screening and monitoring.

An observational study of 30 subjects: subjective opioid withdrawal scores fell by more than half within roughly three days of treatment, 50% reported no opioid use at 1-month follow-up, and improvements in drug-use outcomes were sustained through the 12-month study period.

An online survey of 88 adults who had taken ibogaine for problematic opioid use: 80% reported that ibogaine eliminated or drastically reduced their withdrawal symptoms. Respondents also reported reduced craving. The authors noted the need for medical supervision given cardiac risks.

Open-label study of 191 patients: ibogaine detoxification was associated with reduced opioid withdrawal signs and reduced drug craving under medical supervision. The authors describe ibogaine as transitioning patients between dependence and abstinence.

The largest real-world ibogaine dataset: 6,000+ medically supervised treatments across 3,000+ patients. 176 data points collected per treatment with longitudinal digital monitoring. 90% of patients self-report treatment success; 100% treatment retention rate. Conditions treated include opioid/alcohol/stimulant addiction, PTSD, TBI, depression, and anxiety. Self-reported clinic data, not peer-reviewed.

Ibogaine session only, no follow-up therapy or support. Patients return to unchanged environments and social triggers. Relapse risk is highest in the first months. No study has quantified aftercare tiers — these are clinical observations.

Weekly therapy sessions and peer support groups for 3+ months post-treatment. Addresses psychological triggers but may miss environmental and social factors.

Structured 6-12 month integration program: weekly therapy, integration coaching, lifestyle restructuring, support groups, family counseling, and regular check-ins. Best long-term outcomes.